Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

51.89
-0.8700-1.65%
Post-market: 51.890.00000.00%17:57 EDT
Volume:303.02K
Turnover:15.68M
Market Cap:3.30B
PE:-18.59
High:52.92
Open:52.92
Low:51.08
Close:52.76
52wk High:58.26
52wk Low:31.42
Shares:63.50M
Float Shares:28.35M
Volume Ratio:0.47
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7908
EPS(LYR):-1.8918
ROE:-40.34%
ROA:-24.99%
PB:9.32
PE(LYR):-27.43

Loading ...

MoonLake Immunotherapeutics Reports Steady R&D Expenses and Increased General Administrative Costs in Q1 2025 Financial Results

Reuters
·
May 13

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

Dow Jones
·
Apr 30

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey
·
Apr 24

MoonLake Obtains $500 Million Facility From Hercules Capital

MT Newswires Live
·
Apr 03

BRIEF-Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates

Reuters
·
Apr 03

MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing

TIPRANKS
·
Apr 03

MoonLake Immunotherap Initiated at Outperform by RBC Capital

Dow Jones
·
Mar 18

RBC Capital Initiates a Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Mar 18

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target

MT Newswires Live
·
Mar 18

MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases

TIPRANKS
·
Mar 12

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow Jones
·
Feb 27

Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals

TIPRANKS
·
Feb 27

Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential

TIPRANKS
·
Feb 27

MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position

TIPRANKS
·
Feb 27

Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments

TIPRANKS
·
Feb 27

MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements

TIPRANKS
·
Feb 26

MoonLake Immunotherapeutics reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 26

MoonLake Immunotherapeutics Q4 Loss Widens

MT Newswires Live
·
Feb 26

MoonLake Q4 2024 GAAP EPS $(0.72) Misses $(0.60) Estimate, Year-end Cash, Cash Equivalents And Short-term Marketable Debt Securities Of $448M Expected To Providing Cash Runway To At Least The End Of 2026

Benzinga
·
Feb 26

Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss

MT Newswires Live
·
Feb 26